GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and liraglutide (Victoza, Saxenda), as well as the dual GIP/GLP-1 receptor agonist tirzepatide (Mounjaro, Zepbound), may contribute to this uncomfortable symptom through their effects on digestion
They treat diabetes in two different ways, but both have been proven highly effective
Lawsuits allege that certain pharmacies failed to properly warn patients of potential risks, resulting in severe gastrointestinal injuries, prolonged vomiting, and other complications
Mounjaro Injection Site Reactions 1 in 10 people may experience injection site reactions, which include swelling, itching, and redness at the injection site
A total of 34% of recipients of a 2 mg dose had gastrointestinal symptoms compared with 30.8% of those receiving a 1 mg dose
While it offers significant benefits, its important to be aware of potential side effects and take necessary precautions to use it safely